Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / MYOV - The Sell-Off In Myovant Is Unjustified By Fundamentals

MYOV - The Sell-Off In Myovant Is Unjustified By Fundamentals

Myovant Sciences Ltd.
  • Myovant has positive Phase 3 results in all 3 indications for its main drug relugolix.
  • The stock has taken a huge dive based on disappointing results on a secondary endpoint of the relugolix Phase 3 prostate cancer trial.
  • Nothing substantial has changed in my view since Myovant was trading far higher than it is today.

For further details see:

The Sell-Off In Myovant Is Unjustified By Fundamentals
Stock Information
Company Name: Myovant Sciences Ltd.
Stock Symbol: MYOV
Market: NYSE
Website: myovant.com
Menu
MYOV MYOV Quote MYOV Short MYOV News MYOV Articles MYOV Message Board
Get MYOV Alerts

News, Short Squeeze, Breakout and More Instantly...